847728-01-2

Basic information

• Product Name: CJ-42794
• Synonyms: 4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]Benzoic acid;(S)-4-(1-(5-chloro-2-(4-fluorophenoxy)benzaMido)ethyl)benzoic acid;CJ-042794;4-((S)-1-(2-(4-fluorophenoxy)-5-chlorobenzamido)ethyl)benzoic acid;CJ-42794
• CAS NO: 847728-01-2
• Molecular Formula: C22H17ClFNO4
• Molecular Weight: 413.83
• Mol File: 847728-01-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 572.7±50.0 °C(Predicted)
• Appearance: /
• Density: 1.347±0.06 g/cm3(Predicted)
• Solubility: insoluble in H2O; ≥11.7 mg/mL in DMSO; ≥54.6 mg/mL in EtOH
• PKA: 4.21±0.10(Predicted)
• CAS DataBase Reference: CJ-42794(CAS DataBase Reference)
• NIST Chemistry Reference: CJ-42794(847728-01-2)
• EPA Substance Registry System: CJ-42794(847728-01-2)

Safety Data

• Hazardous Substances Data: 847728-01-2(Hazardous Substances Data)

Usage

Biological Activity

ki: 3.16 nm: antagonizes e prostanoid receptor 4 (ep4).ki: 631 nm: antagonizes ep2.cj-42794, as a selective antagonist of ep4, less binds to ep2 and does not have binding affinity for ep1 or ep3. it displays minimal effect on numerous other receptors, channels, or enzymes. cj-42794 delays the healing of gastric ulcers, inhibiting the upregulation of vegf expression and angiogenesis. ep4, activated by prostaglandin e2 (pge2), is a g-protein-coupled receptor, which plays vital roles in bone formation and resorption, cancer, and atherosclerosis via elevating the second messenger cyclic amp (camp).

in vitro

cj-42794 exhibited remarkable binding activity to ep4 and suppressed pge2-triggered elevations of intracellular camp levels in a concentration-dependent fashion in hek293 cells overexpressing human ep4. moreover, cj-42794, concentration-dependently, reversed the inhibitory effects of pge2 on lipopolysaccharide-evoked tumor necrosis factor α production, which suggested that cj-42794 had excellent pharmacological properties used for exploring the physiological role of ep4 [1].

in vivo

male sprague-dawley rats and c57bl/6 mice were given subcutaneously 3 and 10 mg/kg for rats, 10 mg/kg for mice once daily for 7 or 14 days. compared to the controls, cj-42794, in a dose-dependent manner, impaired and delayed the gastric ulcer healing in rats and mice. cj-42794 markedly dampened the increase of vegf expression in ulcerated mucosa of the mouse stomach and the primary gastric fibroblasts of rat [2].

references

[1]. murase, a., taniguchi, y., tonai-kachi, h., nakao, k., & takada, j. in vitro pharmacological characterization of cj-042794, a novel, potent, and selective prostaglandin ep4 receptor antagonist. life sciences. 2008; 82(3-4): 226-232. [2]. hatazawa, r., tanaka, a., tanigami, m., amagase, k., kato, s., ashida, y., & takeuchi, k. cyclooxygenase-2/prostaglandin e2 accelerates the healing of gastric ulcers via ep4 receptors. ajp: gastrointestinal and liver physiology. 2007; 293(4): g788-g797.

Relevant articles and documents

PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS

This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the li